Search Results

You are looking at 181 - 190 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

. Enrollment is ongoing to obtain more safety data. In general, the degree of esophagitis was mild. Full assessment of survival and correlative studies will be analyzed at study completion. AB2013-2. Interim Results for Neoadjuvant Bevacizumab With Weekly

Full access

Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

prognosis. 2 Standard treatment for mCRC includes infusion of 5-FU plus leucovorin and oxaliplatin (FOLFOX) or infusion of 5-FU plus leucovorin and irinotecan (FOLFIRI), 3 , 4 alone or in combination with bevacizumab, 5 cetuximab, 6 or panitumumab. 7

Full access

Pre-Judging Data: Benchmarking Clinical Significance Before Study Results Are Known

Harold J. Burstein

vs. 2 years is not yet available), and ECOG 5103, which compared chemotherapy alone versus chemotherapy with bevacizumab as adjuvant treatment. These large multicenter studies have long since closed to accrual, and we are waiting for the clinical

Full access

The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value

Doreen A. Ezeife, Sunil Parimi, Ellen R. Cusano, Matthew K. Smith, Tony H. Truong, Soundouss Raissouni, Yongtao Lin, Jose G. Monzon, Haocheng Li, Vincent C. Tam, and Patricia A. Tang

. Table 4 shows the NHB score and the associated incremental cost of 4 mCRC regimens for which information was publically available. The bevacizumab/capecitabine regimen achieved the highest NHB score; however, it also had the highest incremental cost and

Full access

Developmental Therapeutics for Myelodysplastic Syndromes

Aung Naing, Lubomir Sokol, and Alan F. List

Association; June 12-15 , 2003 ; Lyon, France . 21. Gotlib J Jamieson C List A . Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS) [abstract] . Blood 2003 ; 102 : 425

Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599 (abstract) . J Clin Oncol 2005 ; 23 ( 16 suppl ): LBA4 . 5. Immerman SC

Full access

A Decade of Progress for Patients With Metastatic Colorectal Cancer: A New Decade in Which Obstacles Loom

Al B. Benson III

, subsets of patients. Within the last year, the FDA approved bevacizumab and ziv-aflibercept for treatment after first progression, and regorafenib for patients with refractory disease. Although clearly a proof of principle, our ability to appropriately

Full access

Small Cell Lung Cancer in Elderly Patients: A Review

Taofeek K. Owonikoko and Suresh Ramalingam

comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer . J Clin Oncol 2006 ; 24 : 5441 – 5447 . 85. Sandler A Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab

Full access

Ovarian Cancer Guidelines: Treatment Progress and Controversies

Robert J. Morgan Jr.

-increasing evidence and amend the NCCN Guidelines. The most current ongoing controversy facing the panel involves the appropriate recommendations for the addition of bevacizumab to initial treatment regimens. The committee is awaiting publication of mature data and

Full access

Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer

Gabrielle B. Rocque, Courtney P. Williams, Bradford E. Jackson, Stacey A. Ingram, Karian I. Halilova, Maria Pisu, Kelly M. Kenzik, Andres Azuero, Andres Forero, and Smita Bhatia

concordance status. The following categories of nonconcordant treatment (n=188) were identified: (1) single-agent HER2-targeted therapy (19%), (2) adjuvant regimens used in the metastatic setting (40%), (3) nonapproved bevacizumab regimens (6%), (4) therapy